{"disease":{"id":"gastrointestinal-carcinoid-tumor","name":"gastrointestinal carcinoid tumor"},"drugs":{"marketed":[],"pipeline":[],"offLabel":[],"totalMarketed":0,"totalPipeline":0},"trials":{"data":[{"nct_id":"NCT04907643","title":"Virtual Reality for GI Cancer Pain to Improve Patient Reported Outcomes","phase":"NA","overall_status":"RECRUITING","enrollment_count":360,"lead_sponsor_name":"Cedars-Sinai Medical Center","has_results":false},{"nct_id":"NCT05176665","title":"EMB-01 in Patients With Advanced/Metastatic Gastrointestinal Cancers","phase":"PHASE1, PHASE2","overall_status":"RECRUITING","enrollment_count":152,"lead_sponsor_name":"Shanghai EpimAb Biotherapeutics Co., Ltd.","has_results":false},{"nct_id":"NCT02859064","title":"Study of Lanreotide in Patients With Metastatic Gastrointestinal Neuroendocrine Tumors Who Are Undergoing Liver-directed Radioembolization With Yttrium-90 Microspheres","phase":"PHASE2","overall_status":"TERMINATED","enrollment_count":6,"lead_sponsor_name":"SCRI Development Innovations, LLC","has_results":true},{"nct_id":"NCT02259725","title":"Regorafenib in Treating Patients With Advanced or Metastatic Neuroendocrine Tumors","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":3,"lead_sponsor_name":"University of Southern California","has_results":true},{"nct_id":"NCT04602117","title":"ISPY-P1.01:Evaluating the Safety of Weekly Paclitaxel With Trastuzumab Duocarmazine (SYD985) in Patients With Metastatic Cancer","phase":"PHASE1","overall_status":"WITHDRAWN","enrollment_count":0,"lead_sponsor_name":"QuantumLeap Healthcare Collaborative","has_results":false},{"nct_id":"NCT00227773","title":"Vatalanib and Octreotide in Treating Patients With Progressive Neuroendocrine Tumors","phase":"PHASE2","overall_status":"WITHDRAWN","enrollment_count":0,"lead_sponsor_name":"Eastern Cooperative Oncology Group","has_results":false}],"total":6},"guidelines":[],"source":"Drug Landscape verified database"}